Cortellis Drugs to Watch in 2020 report

The drug must leverage its competitive profile as it will face significant competition from entrenched biological agents (and biosimilar versions), including Humira and Enbrel, as well as direct competition from other

Pharma funding and M&A in 2020

a cool $63bn (which was also notable for putting the world’s best-selling drug Humira under the same roof as Botox).

AbbVie/Allergan merger faces renewed public opposition despite divestments

AbbVie. They also highlighted AbbVie’s use of controversial “rebate walls” around its blockbuster immunology products – including Humira and Skyrizi – which the groups say “lead to higher prescription drug prices” and

After FDA refusal, Takeda builds case for subcutaneous Entyvio

AbbVie’s TNF blocker Humira (adalimumab) in a head-to-head trial. ... Analysts at GlobalData have previously suggested that having two formulations of vedolizumab will allow Takeda to compete strongly against well-established ulcerative colitis drugs

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]